Production of Diagnostic and Therapeutic Radionuclides with Uranium and Thorium Molten Salt Fuel Cycles
Open Access
- 23 January 2026
- journal article
- research article
- Published by MDPI AG in Journal of Nuclear Engineering
- Vol. 7 (1) , 9
Abstract
Targeted radionuclide therapy (TRT) is an innovative and flexible approach for treating various forms of cancer, enabling selective delivery of cytotoxic radiation to cancerous cells while minimizing damage to healthy tissue. Although TRT has proven to be highly promising for treating even advanced-stage cancers, ensuring a stable supply of the radionuclides essential for its use remains a significant challenge today. This is also true for radionuclides utilized in nuclear imaging procedures, such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT). Liquid-fueled molten salt reactors (MSRs) are promising for producing large quantities of highly desirable radionuclides for imaging and therapy, offering the ability to recover these radionuclides online without the need for interruptions to power production. In this study, the production of numerous beta- and alpha-emitting radionuclides for use in TRT and diagnostic procedures was studied in two small, geometrically identical, thermal spectrum MSR models—one operating with LEU fuel, and the other with a mixture of HALEU and thorium—using a novel MSR refueling and waste management concept. For therapeutic alpha emitters such as 225Ac and 213Bi, the impact of thorium utilization on production yields was significant, facilitating greatly increased production.Keywords
Funding Information
- U.S. Department of Energy University Nuclear Leadership Program (DE-NE0009082)
This publication has 87 references indexed in Scilit:
- Review of Recent Advances in Electrochemical Processes in Molten Salt Electrolyte for Recycling Used Nuclear FuelKorean Journal of Chemical Engineering, 2024
- Molecular Imaging and Targeted Therapy2023
- Study on the production characteristics of 131I and 90Sr isotopes in a molten salt reactorNuclear Science and Techniques, 2021
- Accelerated aging among childhood, adolescent, and young adult cancer survivors is evidenced by increased expression of p16INK4a and frailtyCancer, 2020
- Targeted Alpha Therapy, an Emerging Class of Cancer AgentsJAMA Oncology, 2018
- 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- Radiolabelled nanoparticles for cancer diagnosisClinical and Translational Imaging, 2018
- Ra‐224 labeling of calcium carbonate microparticles for internal α‐therapy: Preparation, stability, and biodistribution in miceJournal of Labelled Compounds and Radiopharmaceuticals, 2018
- A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant diseaseBreast Cancer Research and Treatment, 2014
- Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014